Login

Journal Front Page

News & Events

  • April 2024 Issue delayed
  • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, Volume 13, Issue 2 (April 2024) Issue) schedule published on 15 April 2024 is delay due to some technical problem. It will published on 22 April 2024. Sorry for inconvenience. For other details You can vist the website http://www.ajper.com
  • Call for article for April 2024 issue
  • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 March, 2024 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • January 2024 Issue published
  • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 13, Issue 1 (January 2024) Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
  • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
  • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
  • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

Formulation, Development and Evaluation of Sustained ReleaseGastroretentive Floating Tablets of Antidiabetic Drug using Natural Polymers

Akash Chandak*, Sunil Kumar Shah, Prabhakar Budholiya, C. K. Tyagi

College of Pharmacy, Sri Satya Sai University of Technology & Medical Sciences, Sehore (M.P.)

ABSTRACT

The major therapeutic goals in subjects with type 2 diabetes are to optimize blood glucose control, induce weight loss, and normalize lipid disturbances and elevated blood pressure. Pioglitazone HCI is a new class of compounds to improve insulin sensitivity in type 2 diabetes. formulation and in vitro evaluation of floating tablet of Pilglitazone HCl. For this purpose, HPMC K4, HPMC K15 and Gaur Gum were incorporated in the formulation and the effect of polymer concentration & viscosity on floating behavior and drug release kinetics was evaluated. In House floating tablet optimized formulation (F7) showed the release of drug form gastroretentive formulation 99.85% after 12 hrs. and marketed formulation showed the release of 98.85% after 1.5 hrs. When the regression coefficient values of were compared, it was observed that ‘r2’ values of first order was maximum i.e. 0.932 hence indicating drug release from formulations was found to follow zero order kinetics, which was sufficient for FGR tablets Pioglitazone HCl. Anomalous transport was confirmed from these tablets which corresponds to diffusion of water and swelling (polymer arrangement) mechanism or mixed order kinetics have an essential role in drug release. This result is encouraging, because a longer gastric residence time is an important condition for higher bioavailability of the drugs included in the FGR release dosage forms. Prepared floating tablets of Pioglitazone HCl may prove to be a potential candidate for safe and effective controlled drug delivery over an extended period of time for gastro retentive drug delivery system.

Keywords: Pioglitazone HCl, Gastro retentive, floating tablet, HPMC, Gaur Gum


[Full Text Article]